Aleph Farms Submits First Ever Application for Cultivated Meat in Europe
26.7.2023 11:00:00 EEST | Business Wire | Press release
Aleph Farms, a cellular agriculture company that enhances sustainability, food security and animal welfare in our food systems, today announced that it has submitted an application for regulatory approval to the Swiss Federal Food Safety and Veterinary Office (FSVO) with the goal of selling the world’s first cultivated beef steaks under the Aleph Cuts brand in Switzerland. The submission is part of Aleph’s collaboration with Migros, Switzerland’s largest food enterprise, which has been instrumental in assessing the country’s specific regulatory approval process.
Aleph Farms is leveraging the expertise and infrastructure of leaders in food production, including Migros, which first invested in the company in 2019, to help accelerate scale-up, go-to-market activities and commercialization of Aleph Cuts worldwide. Together, Aleph and Migros have since conducted extensive consumer research in Switzerland and navigated the intricacies of the country’s regulatory landscape for novel foods. As part of their agreement, the two companies will continue to develop a go-to-market strategy that involves distribution and commercialization of Aleph Cuts through fine dining food service channels in Switzerland.
“Food systems affect everyone, and it will take a coordinated effort between regulators, innovators and incumbents to ensure food security in a way that helps humanity live within its planetary boundaries,” said Didier Toubia, Co-Founder and CEO of Aleph Farms. “At Aleph Farms, we carefully consider partnerships that reflect our core values and sustainability commitments. Together with Migros, we are establishing the cow cell as the third category of food products from cattle, alongside beef and milk. We look forward to working closely with Switzerland's Federal Food Safety and Veterinary Office to enable access to both high-quality nutrition and world-changing innovation.”
Switzerland is a country with a high affinity for innovation. According to research conducted jointly by Aleph Farms and Migros, 74% of Swiss consumers are open to trying cultivated meat and are motivated to try it chiefly by curiosity and a desire to align with principles like sustainability and animal welfare.
Alongside sustainable animal agriculture, cellular agriculture can help increase resilience and stability in the supply of animal proteins and fats to diners in Switzerland. In addition, acceptance by Swiss consumers – known for a quality-conscious attitude towards food – can contribute further to cultivated meat’s growing momentum worldwide.
Later this year, Aleph Farms plans to launch Aleph Cuts in Singapore and Israel in limited quantities and offer exclusive tasting experiences curated with select partners, pending regulatory approvals. Aleph’s regulatory team is working in similar fashion with regulatory authorities in numerous markets around the world, including Switzerland, in order to ensure compliance with respective safety requirements.
About Aleph Farms
Aleph Farms, an Israel-based cellular agriculture company, enhances sustainability, food security and animal welfare in our food systems by diversifying the supply and decentralizing the production of quality animal proteins and fats as a complement to sustainable animal agriculture.
Founded in 2017, the company unveiled the world’s first cultivated thin-cut beef steak in 2018, the world’s first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts, the company is launching its first product, the cultivated Petit Steak, grown from non-modified cells of a premium Black Angus cow.
For its contributions to climate leadership including a net zero commitment made in 2020, the company has received top accolades from the World Economic Forum and the United Nations.
For more information, follow Aleph Cuts on Instagram and Facebook, Aleph Farms on Twitter and Linkedin, or visit www.aleph-farms.com. Access our press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726122722/en/
Contact information
Natalee Gibson
alephfarms@songuepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
